Product Name: ERK1 (199-206) pT202+pY204
Product Number: PE-04ATN01
| Size: | 200 µg | Price: | 39.00 | |
| 1 mg | $US | 78.00 |
Peptide Name: ERK1 (199-206) pT202+pY204
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T202 and Y204 phosphorylation stimulates phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: GFL-pT-E-pY-VA
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T202 and Y204 phosphorylation stimulates phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: GFL-pT-E-pY-VA
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1058.0 Da
Peptide Purity Percent after Synthesis and Purification: >70
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: stable
Peptide Purity Percent after Synthesis and Purification: >70
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: stable
Scientific Background: ERK1 (MAPK3) is a protein-serine/threonine kinase of the CMGC group and MAPK family. It functions as a central component of the MAP kinase intracellular signalling pathway. Phosphorylation at T202 and Y204 by MEK1 and MEK2 increases its phosphotransferase activity. Depending on the cellular context, this pathway is involved in the regulation of cell growth, survival, adhesion, or differentiation. More than 500 substrates have been identified for these MAP kinases. ERK1 activation leads to its translocation from the cytosol to the nucleus where it can target substrate proteins involved in cell cycle regulation; Cyclin D1, suppression of apoptosis; BCL2 and BAD, tumour supression; p53, cell migration; PAI-1, and MHCII mediated immune response; PPARg1. ERK1 appears to be a tumour requiring protein (TRP). The active form of the protein kinase normally acts to promote tumour cell proliferation. Dysfunction of MAPK3 expression and activity has been observed in a variety of cancers. Predominantly over-expression of MAPK3 or constitutive activation has been observed in cancer cell lines. Generally, activation of MAPK3 does not appear to be due to mutations in the protein itself but rather aberrant signalling in upstream factors including Raf, Ras and epidermal growth factor receptor. MAPK3 may also have a role in promoting metastasis in invasive tumours. Mutations resulting in the activation of the MAPK3 protein, but not necessary the over-expression of the MAPK3 protein, have been associated with tumourigenesis in several cancer types.
© Kinexus Bioinformatics Corporation 2017